Published in Protein Sci on December 29, 2005
Dual detection of fungal infections in Drosophila via recognition of glucans and sensing of virulence factors. Cell (2006) 2.66
Inhibition of protein aggregation: supramolecular assemblies of arginine hold the key. PLoS One (2007) 1.02
The N-terminal domain of Drosophila Gram-negative binding protein 3 (GNBP3) defines a novel family of fungal pattern recognition receptors. J Biol Chem (2009) 1.02
Solution structure of the silkworm betaGRP/GNBP3 N-terminal domain reveals the mechanism for beta-1,3-glucan-specific recognition. Proc Natl Acad Sci U S A (2009) 0.98
Purification and protective efficacy of monomeric and modified Yersinia pestis capsular F1-V antigen fusion proteins for vaccination against plague. Protein Expr Purif (2006) 0.93
Characterization of neuronal Src kinase purified from a bacterial expression system. Protein Expr Purif (2010) 0.81
Gene silencing by cell-penetrating, sequence-selective and nucleic-acid hydrolyzing antibodies. Nucleic Acids Res (2009) 0.80
Refolding by high pressure of a toxin containing seven disulfide bonds: bothropstoxin-1 from Bothrops jararacussu. Mol Biotechnol (2011) 0.78
The Influence of Arginine on the Response of Enamel Matrix Derivative (EMD) Proteins to Thermal Stress: Towards Improving the Stability of EMD-Based Products. PLoS One (2015) 0.75
Lid mobility in lipase SMG1 validated using a thiol/disulfide redox potential probe. FEBS Open Bio (2016) 0.75
A simple method for displaying the hydropathic character of a protein. J Mol Biol (1982) 150.65
Pressure stability of proteins. Annu Rev Phys Chem (1993) 3.31
A family of peptidoglycan recognition proteins in the fruit fly Drosophila melanogaster. Proc Natl Acad Sci U S A (2000) 3.08
Control of protein stability and reactions by weakly interacting cosolvents: the simplicity of the complicated. Adv Protein Chem (1998) 2.54
Proteins under pressure. The influence of high hydrostatic pressure on structure, function and assembly of proteins and protein complexes. Eur J Biochem (1994) 2.30
Reversible pressure--temperature denaturation of chymotrypsinogen. Biochemistry (1971) 2.17
Gram-negative bacteria-binding protein, a pattern recognition receptor for lipopolysaccharide and beta-1,3-glucan that mediates the signaling for the induction of innate immune genes in Drosophila melanogaster cells. J Biol Chem (2000) 2.05
MKP-3, a novel cytosolic protein-tyrosine phosphatase that exemplifies a new class of mitogen-activated protein kinase phosphatase. J Biol Chem (1996) 2.03
Sensing and signaling during infection in Drosophila. Curr Opin Immunol (2005) 1.49
Inhibition of aggregation side reactions during in vitro protein folding. Methods Enzymol (1999) 1.45
Preparative protein refolding. Trends Biotechnol (2002) 1.44
Structure and morphology of protein inclusion bodies in Escherichia coli. Biotechnology (N Y) (1991) 1.44
Protein tyrosine phosphatase: enzymatic assays. Methods (2005) 1.42
The effects of arginine on refolding of aggregated proteins: not facilitate refolding, but suppress aggregation. Biochem Biophys Res Commun (2003) 1.35
Role of arginine in the stabilization of proteins against aggregation. Biochemistry (2005) 1.28
Dissociation of amyloid fibrils of alpha-synuclein and transthyretin by pressure reveals their reversible nature and the formation of water-excluded cavities. Proc Natl Acad Sci U S A (2003) 1.26
Biophysical effect of amino acids on the prevention of protein aggregation. J Biochem (2002) 1.24
The preaggregated state of an amyloidogenic protein: hydrostatic pressure converts native transthyretin into the amyloidogenic state. Proc Natl Acad Sci U S A (2000) 1.21
A new protein folding screen: application to the ligand binding domains of a glutamate and kainate receptor and to lysozyme and carbonic anhydrase. Protein Sci (1999) 1.17
Effect of Tween 20 on freeze-thawing- and agitation-induced aggregation of recombinant human factor XIII. J Pharm Sci (1998) 1.16
High pressure fosters protein refolding from aggregates at high concentrations. Proc Natl Acad Sci U S A (1999) 1.14
Control of aggregation in protein refolding: a variety of surfactants promote renaturation of carbonic anhydrase II. Protein Sci (1995) 1.06
Counteracting effects of renal solutes on amyloid fibril formation by immunoglobulin light chains. J Biol Chem (2001) 1.03
Oxidative renaturation of hen egg-white lysozyme. Folding vs aggregation. Biotechnol Prog (1998) 0.99
Rational design of solution additives for the prevention of protein aggregation. Biophys J (2004) 0.99
Exploring the temperature-pressure configurational landscape of biomolecules: from lipid membranes to proteins. Philos Trans A Math Phys Eng Sci (2005) 0.99
L-Arginine increases the solubility of unfolded species of hen egg white lysozyme. Protein Sci (2005) 0.97
Pressure treatment of tailspike aggregates rapidly produces on-pathway folding intermediates. Biotechnol Bioeng (2003) 0.95
Method for increasing the yield of properly folded recombinant human gamma interferon from inclusion bodies. J Biotechnol (1996) 0.95
High hydrostatic pressure can reverse aggregation of protein folding intermediates and facilitate acquisition of native structure. Biochemistry (1998) 0.93
High hydrostatic pressure as a tool to study protein aggregation and amyloidosis. Biochim Biophys Acta (2002) 0.92
Is arginine a protein-denaturant? Protein Expr Purif (2005) 0.89
High-pressure refolding of bikunin: efficacy and thermodynamics. Protein Sci (2004) 0.87
High pressure refolding of recombinant human growth hormone from insoluble aggregates. Structural transformations, kinetic barriers, and energetics. J Biol Chem (2001) 0.86
Estimating the potential refolding yield of recombinant proteins expressed as inclusion bodies. Biotechnol Bioeng (2004) 0.85
The effects of Tween 20 and sucrose on the stability of anti-L-selectin during lyophilization and reconstitution. J Pharm Sci (2001) 0.85
Effect of additives on refolding of a denatured protein. Biotechnol Prog (1999) 0.84
Natural osmolyte trimethylamine N-oxide stimulates tubulin polymerization and reverses urea inhibition. Am J Physiol (1997) 0.84
High-pressure refolding of disulfide-cross-linked lysozyme aggregates: thermodynamics and optimization. Biotechnol Prog (2002) 0.81
Acid- and pressure-induced (un)folding of yeast glutathione reductase: competition between protein oligomerization and aggregation. Int J Biochem Cell Biol (2005) 0.78
Physical mapping of receptor type protein tyrosine phosphatase sigma (PTPRS) to human chromosome 19p13.3. Genomics (1996) 0.78
Physical stability of proteins in aqueous solution: mechanism and driving forces in nonnative protein aggregation. Pharm Res (2003) 4.01
Overlooking subvisible particles in therapeutic protein products: gaps that may compromise product quality. J Pharm Sci (2009) 2.36
Roles of conformational stability and colloidal stability in the aggregation of recombinant human granulocyte colony-stimulating factor. Protein Sci (2003) 1.51
High-molecular-weight aggregates in repackaged bevacizumab. Retina (2010) 1.45
Expression profiling and subtype-specific expression of stomach cancer. Cancer Res (2003) 1.43
IgG particle formation during filling pump operation: a case study of heterogeneous nucleation on stainless steel nanoparticles. J Pharm Sci (2009) 1.41
Domain-level antibody epitope mapping through yeast surface display of epidermal growth factor receptor fragments. J Immunol Methods (2004) 1.39
Heterogeneous nucleation-controlled particulate formation of recombinant human platelet-activating factor acetylhydrolase in pharmaceutical formulation. J Pharm Sci (2005) 1.33
Directed evolution to probe protein allostery and integrin I domains of 200,000-fold higher affinity. Proc Natl Acad Sci U S A (2006) 1.32
Application of a weights-of-evidence method and GIS to regional groundwater productivity potential mapping. J Environ Manage (2011) 1.28
Oxidative dimer formation is the critical rate-limiting step for Parkinson's disease alpha-synuclein fibrillogenesis. Biochemistry (2003) 1.27
Quantitation of aggregate levels in a recombinant humanized monoclonal antibody formulation by size-exclusion chromatography, asymmetrical flow field flow fractionation, and sedimentation velocity. J Pharm Sci (2007) 1.27
Identification of the epitope for the epidermal growth factor receptor-specific monoclonal antibody 806 reveals that it preferentially recognizes an untethered form of the receptor. J Biol Chem (2004) 1.23
Screening and characterization of a novel esterase from a metagenomic library. Protein Expr Purif (2005) 1.22
Rescue of cystathionine beta-synthase (CBS) mutants with chemical chaperones: purification and characterization of eight CBS mutant enzymes. J Biol Chem (2010) 1.20
A human scFv antibody against TRAIL receptor 2 induces autophagic cell death in both TRAIL-sensitive and TRAIL-resistant cancer cells. Cancer Res (2007) 1.19
Silicone oil- and agitation-induced aggregation of a monoclonal antibody in aqueous solution. J Pharm Sci (2009) 1.18
Silicone oil microdroplets and protein aggregates in repackaged bevacizumab and ranibizumab: effects of long-term storage and product mishandling. Invest Ophthalmol Vis Sci (2011) 1.17
Response of a concentrated monoclonal antibody formulation to high shear. Biotechnol Bioeng (2009) 1.17
Effects of solution conditions, processing parameters, and container materials on aggregation of a monoclonal antibody during freeze-thawing. J Pharm Sci (2008) 1.16
Potential inaccurate quantitation and sizing of protein aggregates by size exclusion chromatography: essential need to use orthogonal methods to assure the quality of therapeutic protein products. J Pharm Sci (2010) 1.16
Heavy and light chain variable single domains of an anti-DNA binding antibody hydrolyze both double- and single-stranded DNAs without sequence specificity. J Biol Chem (2006) 1.14
BSA degradation under acidic conditions: a model for protein instability during release from PLGA delivery systems. J Pharm Sci (2006) 1.11
Immunogenicity of aggregates of recombinant human growth hormone in mouse models. J Pharm Sci (2009) 1.10
Congo red populates partially unfolded states of an amyloidogenic protein to enhance aggregation and amyloid fibril formation. J Biol Chem (2003) 1.10
Precipitation of a monoclonal antibody by soluble tungsten. J Pharm Sci (2009) 1.10
VDUP1 mediates nuclear export of HIF1alpha via CRM1-dependent pathway. Biochim Biophys Acta (2007) 1.08
Understanding and modulating opalescence and viscosity in a monoclonal antibody formulation. J Pharm Sci (2010) 1.08
Effects of Tween 20 and Tween 80 on the stability of Albutropin during agitation. J Pharm Sci (2005) 1.08
Aggregation of granulocyte colony stimulating factor under physiological conditions: characterization and thermodynamic inhibition. Biochemistry (2002) 1.07
Upregulation of Beclin-1 expression and phosphorylation of Bcl-2 and p53 are involved in the JNK-mediated autophagic cell death. Biochem Biophys Res Commun (2009) 1.05
Protein adsorption and excipient effects on kinetic stability of silicone oil emulsions. J Pharm Sci (2010) 1.05
Sedimentation velocity analytical ultracentrifugation and SEDFIT/c(s): limits of quantitation for a monoclonal antibody system. Anal Biochem (2006) 1.04
Mechanisms involved in the protection of UV-induced protein inactivation by the corneal crystallin ALDH3A1. J Biol Chem (2006) 1.03
Effects of sucrose on conformational equilibria and fluctuations within the native-state ensemble of proteins. Protein Sci (2003) 1.02
A surface plasmon enhanced infrared photodetector based on InAs quantum dots. Nano Lett (2010) 1.01
Inhibition of aggregation of aluminum hydroxide adjuvant during freezing and drying. J Pharm Sci (2008) 1.01
High-resolution structure of ybfF from Escherichia coli K12: a unique substrate-binding crevice generated by domain arrangement. J Mol Biol (2008) 1.01
Improved mutants from directed evolution are biased to orthologous substitutions. Protein Eng Des Sel (2006) 1.00
Surface adsorption of recombinant human interferon-gamma in lyophilized and spray-lyophilized formulations. J Pharm Sci (2002) 1.00
Characterization and quantitation of aggregates and particles in interferon-β products: potential links between product quality attributes and immunogenicity. J Pharm Sci (2012) 1.00
Comparative analyses of complex formation and binding sites between human tumor necrosis factor-alpha and its three antagonists elucidate their different neutralizing mechanisms. J Mol Biol (2007) 0.99
Influence of particle size and antigen binding on effectiveness of aluminum salt adjuvants in a model lysozyme vaccine. J Pharm Sci (2008) 0.98
Rational design of stable lyophilized protein formulations: theory and practice. Pharm Biotechnol (2002) 0.98
Gender-dependent hepatic alterations in H-ras12V transgenic mice. J Hepatol (2005) 0.98
Solid state chemistry of proteins: II. The correlation of storage stability of freeze-dried human growth hormone (hGH) with structure and dynamics in the glassy solid. J Pharm Sci (2008) 0.98
Novel candidate targets of Wnt/beta-catenin signaling in hepatoma cells. Life Sci (2006) 0.98
Monoclonal antibody interactions with micro- and nanoparticles: adsorption, aggregation, and accelerated stress studies. J Pharm Sci (2009) 0.98
High prevalence of RET, RAS, and ERK expression in Hashimoto's thyroiditis and in papillary thyroid carcinoma in the Korean population. Thyroid (2007) 0.98
Aggregation of a monoclonal antibody induced by adsorption to stainless steel. Biotechnol Bioeng (2010) 0.97
Ligand-induced conformational and structural dynamics changes in Escherichia coli cyclic AMP receptor protein. Biochemistry (2002) 0.96
Kinetics and energetics of assembly, nucleation, and growth of aggregates and fibrils for an amyloidogenic protein. Insights into transition states from pressure, temperature, and co-solute studies. J Biol Chem (2002) 0.96
Effects of pH, temperature, and sucrose on benzyl alcohol-induced aggregation of recombinant human granulocyte colony stimulating factor. J Pharm Sci (2006) 0.96
Common excipients impair detection of protein aggregates during sedimentation velocity analytical ultracentrifugation. J Pharm Sci (2009) 0.95
Mechanism for benzyl alcohol-induced aggregation of recombinant human interleukin-1 receptor antagonist in aqueous solution. J Pharm Sci (2004) 0.95
High concentration formulations of recombinant human interleukin-1 receptor antagonist: II. Aggregation kinetics. J Pharm Sci (2008) 0.95
Homomeric and heteromeric interactions of the extracellular domains of death receptors and death decoy receptors. Biochem Biophys Res Commun (2005) 0.94
Protein instability and immunogenicity: roadblocks to clinical application of injectable protein delivery systems for sustained release. J Pharm Sci (2011) 0.94
Oxidation of methionine residues in recombinant human interleukin-1 receptor antagonist: implications of conformational stability on protein oxidation kinetics. Biochemistry (2007) 0.93
Cryopreservation of stem cells using trehalose: evaluation of the method using a human hematopoietic cell line. Stem Cells Dev (2004) 0.93
High-level production of arachidonic acid by fed-batch culture of Mortierella alpina using NH4OH as a nitrogen source and pH control. Biotechnol Lett (2005) 0.93
Glass particles as an adjuvant: a model for adverse immunogenicity of therapeutic proteins. J Pharm Sci (2011) 0.92
High hydrostatic pressure as a tool to study protein aggregation and amyloidosis. Biochim Biophys Acta (2002) 0.92
Protein formulation and fill-finish operations. Biotechnol Annu Rev (2002) 0.92
Effects of surfaces and leachables on the stability of biopharmaceuticals. J Pharm Sci (2011) 0.91